The Readout Loud
290: Biotech layoffs, slumping stocks, and a 2024 preview
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.